» Articles » PMID: 27264777

Management of Chronic Obstructive Pulmonary Disease Beyond the Lungs

Overview
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2016 Jun 7
PMID 27264777
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic obstructive pulmonary disease (COPD) is an umbrella term that covers many clinical subtypes with clearly different pulmonary and extra-pulmonary characteristics, but with persistent airflow limitation in common. This insight has led to the development of a more personalised approach in bronchodilator therapy, prevention of exacerbations, and advanced treatments (such as non-invasive ventilation and lung volume reduction techniques). However, systemic manifestations and comorbidities of COPD also contribute to different clinical phenotypes and warrant an individualised approach as part of integrated disease management. Alterations in bodyweight and composition, from cachexia to obesity, demand specific management. Psychological symptoms are highly prevalent, and thorough diagnosis and treatment are necessary. Moreover, prevention of exacerbations requires interventions beyond the lungs, including treatment of gastro-oesophageal reflux disease, reduction of cardiovascular risks, and management of dyspnoea and anxiety. In this Review, we discuss the management of COPD beyond the respiratory system and propose treatment strategies on the basis of the latest research and best practices.

Citing Articles

Association of life's essential 8 with chronic obstructive pulmonary disease: a population-based analysis of NHANES 2007-2018.

Liu Y, Li W, Tang J, Gao S BMC Public Health. 2024; 24(1):3144.

PMID: 39538175 PMC: 11558873. DOI: 10.1186/s12889-024-20534-5.


Prevalence and predictors of polypharmacy and comorbidities among patients with chronic obstructive pulmonary disease: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia.

Alwafi H, Naser A, Ashoor D, Alsharif A, Aldhahir A, Alghamdi S BMC Pulm Med. 2024; 24(1):453.

PMID: 39272014 PMC: 11401255. DOI: 10.1186/s12890-024-03274-5.


Symptom burden and its associations with clinical characteristics in patients with COPD: a clustering approach.

Houben-Wilke S, Deng Q, Janssen D, Franssen F, Spruit M ERJ Open Res. 2024; 10(4).

PMID: 39104954 PMC: 11299006. DOI: 10.1183/23120541.01052-2023.


Lung Hyperinflation as Treatable Trait in Chronic Obstructive Pulmonary Disease: A Narrative Review.

Koopman M, Posthuma R, Vanfleteren L, Simons S, Franssen F Int J Chron Obstruct Pulmon Dis. 2024; 19:1561-1578.

PMID: 38974815 PMC: 11227310. DOI: 10.2147/COPD.S458324.


Chitosan-Based Nanocarriers for Pulmonary and Intranasal Drug Delivery Systems: A Comprehensive Overview of their Applications.

Alwahsh W, Sahudin S, AlKhatib H, Bostanudin M, Alwahsh M Curr Drug Targets. 2024; 25(7):492-511.

PMID: 38676513 DOI: 10.2174/0113894501301747240417103321.